Shortage of glycopyrrolate 200 mg/mL injection

The Issue:
There is a shortage of all sizes of glycopyrrolate 200 mg/mL injection. Sandoz, the only Canadian manufacturer of this product, is working through regulatory issues at their facility in Quebec and production is reduced. We are still receiving small quantities of drug, but stock levels are critically low and will not meet current demands.

Key changes include:
- Prescribers should be aware of the shortage of glycopyrrolate injection
- Available alternatives include the following, as clinically appropriate:
  - Atropine injection - alternative chronotropic agent
  - Scopolamine injection - alternative antimuscarinic for drying secretions

Action:
Please post this notice in your area and ensure that all staff are informed of this change.

Contact:
Site Pharmacy Department for any questions or concerns.

Prepared by: Tracey Simpson, Manager, Procurement, Inventory & Service Performance